New book by former FDA head explores the science behind GLP-1 weight loss drugs
According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs containing GLP-1, a hormone that slows digestion and helps with sustained weight loss. In a new book, former FDA head Dr. David Kessler advocates for their use, but says they shouldn’t be […]
With China approval, Lilly and Innovent’s mazdutide breaks into new class for GLP-1 obesity drugs – Fierce Pharma
With China approval, Lilly and Innovent’s mazdutide breaks into new class for GLP-1 obesity drugs Fierce Pharma
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
OPKO Health, Inc. (NASDAQ:OPK) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company, in partnership with Entera Bio Ltd., announced that new data for their investigational oral OPK-88006 tablet treatment has been selected for presentation at ENDO 2025. 15 States with the Best Healthcare in […]
Retatrutide: arguable the most effective metabolic drug ever developed. Full steam for LLY
Surprised how little attention Retatrutide is getting, even though it has the potential to be the most effective obesity and metabolic disease drug ever developed. Eli Lilly is leading the market with Mounjaro and Zepbound, but retatrutide, their next generation triple agonist targeting GLP 1, GIP, and glucagon receptors, could surpass both. I work in […]
UPSC Key: Roadmap on de-escalation, GLP-1 drugs, and Coastline paradox
Post Content
Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize
Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Leave Wall Street Stunned. Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive’s reaffirmation that the company will continue to offer cheaper compounded versions of GLP-1 weight-loss drugs, […]
Why Thousands Are Risking DIY Weight-Loss Injections
High prices and limited insurance coverage have driven a growing number of Americans to seek weight-loss solutions outside the doctor’s office and the law. Online forums, encrypted chat groups, and underground vendors are fueling a gray market for injectable obesity drugs, often sourced from unregulated suppliers overseas. At the heart of this trend are popular […]
768-P: Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Motility-Related Gastrointestinal Adverse Events—A Cohort Study
Introduction and Objective: To assess if glucagon-like peptide-1 receptor agonist (GLP-1 RA) compared with sodium-glucose cotransporter 2 inhibitors (SGLT-2i), is associated with an increased risk of motility-related gastrointestinal (GI) adverse events.Methods: From two US commercial healthcare databases, we used 1-1 propensity score matching on >150 potential confounders to identify a cohort of adults with type […]
750-P: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study
Introduction and Objective: ASC30 is an oral GLP-1R biased small molecule agonist without β-arrestin recruitment, discovered and developed in-house at Ascletis. ASC30 has unique and differentiated properties that enable the administration of one small molecule as both a once-monthly subcutaneous injection and a once-daily oral tablet. The current study assessed safety, tolerability and pharmacokinetics of […]